News >

Neoadjuvant Nivolumab Shows Strong Clinical Activity in Merkel Cell Carcinoma

Brittany Cote
Published: Monday, May 04, 2020

Suzanne L. Topalian, MD

Suzanne L. Topalian, MD

Nivolumab (Opdivo), when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma (MCC), was found to be tolerable and to induce pathological complete responses (pCRs) as well as radiographic tumor regressions in about half of treated patients, according to results from the phase 1/2 CheckMate-358 trial. 1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication